more...

>

Intellectual Property

>

Success and Statistics

>

TransGenRx TransGenRx, a biopharmaceutical manufacturing company, has developed technology that significantly reduces the cost of producing protein-based drugs by using a high-expressing avian cell line combined with their patented vector system. Patented and patent pending processes allow TGRx to develop custom proteins to meet a wide range of specifications. Dr. Richard Cooper, a professor in the AgCenter Department of Veterinary Science, serves as the company's Executive Vice President of Research and Development. Since its inception, the company has won an STTR phase II award and has won contracts with drug manufacturers for its proteins and hormones. June 6, 2003 LSU AgCenter Announces Biotechnology Breakthrough August 2005 TGRx Wins 2005 ‘Quality Award’ from U.S. Army  October 29, 2009 TransGenRx wins hormone contract February 9, 2012 TransGenRx signs agreement with Novocyt To find more information about TransGenRx, visit: http://www.tgrxinc.com/

Last Updated: 5/25/2012 12:43:20 PM